Join
Live feed
·
PRReleasevia Quantisnow
Vaxcyte Inc. logo

Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte's 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate

ByQuantisnow·Wall Street's wire, on your screen.
PCVX· Vaxcyte Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PCVX (Vaxcyte Inc.) and more on Quantisnow.